LATEST

Smoking linked to tumor heterogeneity for bladder CaResearchers from Wake Forest Baptist Comprehensive Cancer Center have made novel discoveries about the genomic signatures of cancers—including bladder cancer—in smokers and African-American patients.
Genomic research may explain resistance to immunotherapyNew research characterizing the molecular mechanisms regulating immune cell infiltration into the luminal subtype of muscle-invasive bladder cancer may explain resistance to treatment with immune checkpoint blockade and suggest a target for improving therapeutic response.
Men must be entitled to PCa screening, treatment choiceThe following letter was sent to Urology Times in response to a previously published letter to the editor, "Dear USPSTF: Don't discount value of PSA in men 70+."
Uro Pipeline: UTI vaccine receives fast track designation from FDAOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
5-ARI may have adverse metabolic effectsAuthors of a recent study say that long-term therapy with a 5-alpha-reductase inhibitor was associated with increased glucose, increased glycated hemoglobin, and altered lipid profiles.
Incontinence after RP or RT: Consider preventive measures firstIn this interview, SUNA President Gwendolyn Hooper, PhD, APRN, discusses practical tips for prevention and management of incontinence in men treated for localized prostate cancer.
Most robotic RPs performed at low-volume hospitalsIn a recent study, increasing hospital volume was significantly associated with improved perioperative outcomes.
Urology-specific quality measures are comingTwo electronic Clinical Quality Measures will help urologists report on prostate and bladder cancer care.
QoL better with bladder Ca immunotherapy vs. chemoPatients treated with pembrolizumab (Keytruda) as second-line therapy for advanced urothelial carcinoma following platinum-based chemotherapy maintain better health-related quality of life than their counterparts receiving chemotherapy, according to results from the phase III KEYNOTE-045 trial presented at the American Society of Clinical Oncology annual meeting in Chicago.
Side effects of modern PCa treatments comparedDespite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study.

Poll